T1	Participants 66 130	patients with chemotherapy-induced painful peripheral neuropathy
T2	Participants 536 624	231 patients who were 25 years or older being treated at community and academic settings
T3	Participants 701 759	Stratified by chemotherapeutic drug and comorbid pain risk
T4	Participants 870 1157	Eligibility required that patients have grade 1 or higher sensory neuropathy according to the NCI Common Terminology Criteria for Adverse Events and at least 4 on a scale of 0 to 10, representing average chemotherapy-induced pain, after paclitaxel, other taxane, or oxaliplatin treatment
T5	Participants 1493 1541	chemotherapy-induced peripheral neuropathic pain
